AACR and Bayer Offering Research Grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research and Bayer announced the 2016 AACR-Bayer Innovation and Discovery Grants program for meritorious projects that examine novel targets and biomarkers in oncology research.

The grants will promote the Bayer Grants4Targets initiative, originally introduced in 2009, to provide new treatment options for cancers with high unmet medical need, encourage innovation and translation of ideas from basic research into novel drugs, and foster collaborations between academic groups and the pharmaceutical industry.

The research proposed for funding should examine novel therapeutic targets focusing on the following oncology research areas: inhibition of cell proliferation; survival signaling; transcription and chromatin modulation; cell cycle regulation; tumor metabolism; hypoxia; immunotherapy; and antibody-drug conjugates.

Each grant will provide $10,000 to $25,000 over a period of one year, with the grant term to begin July 1. All the recipients will be offered the opportunity to work with a Bayer mentor who will provide guidance, expertise, and/or tools to accelerate the translation of their scientific idea.

To complete an application, please visit http://myaacr.aacr.org. Applications must be submitted by Jan. 18. Additional inquiries may be directed to Shaun Fitzpatrick at grants@aacr.org.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login